Besides, immunotherapy reactivating CD8+ T cells such as anti-PD-1 antibodies exhibits tumor therapeutic promise against NSCLC, and results in 20% tumor remission in the patients’ failed treatments of chemotherapies or targeted therapies [8,9,10]. This evidence concerns the gene CD8A and neoplasm.